Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600129124) titled 'A Discrete Choice Experiment Questionnaire Study on Adjuvant Treatment Preferences in Patients with HR+/HER2- Early Breast Cancer' on July 31.
Study Type: Observational study
Study Design:
Cross-sectional
Primary Sponsor: Ningbo Medical Centre Lihuili Hospital
Condition:
HR-positive, HER2-negative early invasive breast cancer
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-08-01
Target Sample Size: Group of Patients with HR+/HER2- Early Breast Cancer:300;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=335107
Published by...